about
Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex.Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple SclerosisCharacterisation of the expression of NMDA receptors in human astrocytesIndoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampusFactors in AIDS dementia complex trial design: results and lessons from the abacavir trialThe NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytesA new era in the treatment of multiple sclerosisTherapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association oPathogenesis and diagnosis of viral infections of the nervous system.Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study.Bcl11b: A New Piece to the Complex Puzzle of Amyotrophic Lateral Sclerosis Neuropathogenesis?The excitotoxin quinolinic acid induces tau phosphorylation in human neuronsExtensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia.Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.Statistical integration of 1H NMR and MRS data from different biofluids and tissues enhances recovery of biological information from individuals with HIV-1 infection.Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO).Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV.Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals.First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia.Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders.Lead dysregulates serine/threonine protein phosphatases in human neurons.Undifferentiated mouse mesenchymal stem cells spontaneously express neural and stem cell markers Oct-4 and Rex-1.Involvement of the kynurenine pathway in human glioma pathophysiology.HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study.HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV researchPosterior reversible encephalopathy syndrome (PRES) in an HIV-1 infected patient with disseminated varicella zoster virus: a case reportQuinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies.Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognitionHIV eradication symposium: will the brain be left behind?Updated research nosology for HIV-associated neurocognitive disordersExpression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative DiseaseDoes use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?Neurological complications of HIV infection.Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activityImplications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis.CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies.Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT(1A) receptors
P50
Q24814135-4D6833C6-F39B-4EE9-BBE9-6888474ECA1EQ26740330-544D51AB-138F-4A0A-B52F-1B854EE49717Q27316321-B4B039A8-F0DC-4B79-8D1D-E609A58B9545Q28260918-30C1635C-B87B-4346-B5F5-5AB702CCE62FQ28469174-9CAD928E-DC1E-414F-B00A-EA3DCDC79419Q28486204-77CCEFF1-BCDC-41CE-94A2-F2EFF8D21720Q29395420-5E0B5E30-1B62-42AC-A5FB-7C1FDF37460DQ30834551-4B789AA0-57A0-4D68-AF44-9CCADAC009C0Q31165334-A9FAA1E8-CE61-40E7-8423-8F2096D0A311Q33265632-552EE706-2168-4440-AEA1-5BED75B6E0F2Q33361902-C4221910-F870-458F-851A-66C49CE7993AQ33485236-E20EE4A8-7364-4025-95FD-FFD87D6D5220Q33501775-B27448A9-51BF-4ED8-8BC6-6BBD30980286Q33520347-B42B63BC-7B80-4A39-AFBC-3A1E79F94953Q33796091-E593FD5C-DC9C-4982-B81F-6A2A2F3E30BBQ33832055-6AC244E4-694F-4E42-AEBD-77EDF2BBEDCCQ33874791-48D0320D-B9E9-4D30-96C5-A38D0EA17DC4Q33916381-15022FB8-9D9C-4129-9219-E6CF09D0A7D0Q33995872-A0FA1833-0D0D-4EA2-8C3A-E4B8F6252DF8Q34007084-9618104F-32E1-4001-A081-279105BDA7F1Q34125560-E9D726EC-50A2-4678-8422-906960B83B75Q34248380-9B073054-D17E-42C5-B895-D670C0A78BC1Q34500924-DFEE7A71-BEB9-4A9C-86DB-5F919C165404Q34541084-EA2B4E46-1F86-410A-82CE-BC6BDAF261E8Q34556982-CF6F5BD8-609C-4852-A779-24CE96A610A5Q34689241-E3BF11AD-0121-4EDF-A81B-4D0ADEBD08C9Q34721127-34DA98A0-9DF4-4D3C-93E2-59D928BEA244Q34975085-00AC0412-13CD-4D69-9CD9-4A5C91791BC7Q34997869-9873F440-2F6B-4D40-BD39-E3B8DAA79787Q35164448-3DC33C12-4B1E-48D4-A91B-F96048892375Q35325801-541BE01E-9A1B-4695-9211-B5752E6FFB33Q35607587-AAED64B6-49F6-4DEF-9B5F-5D55831E2937Q35755761-9BC181B3-507F-4072-B464-68C1CA9E1A2AQ35788146-7001B00E-B6CD-4BF6-B07B-E0C798C289E5Q35877689-5A4E80C1-EB83-4C6B-89FC-683E7C9E311CQ36234349-5B45E808-EB1B-4B4B-B4A1-4970EB3B4548Q36298436-54A188D1-EA5B-420E-BEA4-D725424DC499Q36565671-E1DF366B-5D91-4B8A-8BF1-256F19D8933CQ36719187-D2B76DCB-76FB-410D-A99E-857AC9D8A616Q36735850-8FBBF074-24FC-454C-B567-A2EB280AC7DC
P50
description
researcher ORCID ID = 0000-0003-0622-1392
@en
wetenschapper
@nl
name
Bruce J Brew
@ast
Bruce J Brew
@de
Bruce J Brew
@en
Bruce J Brew
@es
Bruce J Brew
@it
Bruce J Brew
@nl
Bruce J Brew
@sq
type
label
Bruce J Brew
@ast
Bruce J Brew
@de
Bruce J Brew
@en
Bruce J Brew
@es
Bruce J Brew
@it
Bruce J Brew
@nl
Bruce J Brew
@sq
prefLabel
Bruce J Brew
@ast
Bruce J Brew
@de
Bruce J Brew
@en
Bruce J Brew
@es
Bruce J Brew
@it
Bruce J Brew
@nl
Bruce J Brew
@sq
P214
P227
P106
P1153
7007185580
P21
P214
P227
1156884128
P31
P496
0000-0003-0622-1392
P735
P7859
viaf-3670152563106515560008